Biden wishes to spend billions more on COVID-19 efforts at home and abroad. US federal funding agencies haven’t discussed specific funding opportunities based on the administration’s proposals, but it is likely there will be more funding available to biotech R&D on anti-virals, vaccines, diagnostics, etc.
Dr. Sarah Fontaine discusses CDMRP non-dilutive funding opportunities for neuroscience R&D.
Dr. Donna Kimbark discusses CDMRP’s unique non-dilutive funding opportunities for cancer R&D.
Dr. Akua Roach discusses non-dilutive funding opportunities through CDMRP.
Dr. William Bozza discusses non-dilutive funding opportunities at NCI and NIH.
Dr. Charles L. Cywin discusses non-dilutive funding opportunities at NINDS and NIH.
Dr. Daniel Gossett discusses non-dilutive funding opportunities at NIDDK and NIH.
Dr. Abla Creasey discusses non-dilutive funding opportunities at the California Institute for Regenerative Medicine, which funds stem cell R&D.
Dr. Natalia Kruchinin discusses non-dilutive funding opportunities at NIAID and NIH.
Nick Damiano, co-founder and CEO of Abalone Bio, discusses the company’s success with non-dilutive funding. Abalone Bio is the first company to win funding from FreeMind Investments.